965PEvaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)
暂无分享，去创建一个
A. Oza | C. Scott | I. Vergote | J. Y. Kim | P. Harter | G. Sonke | T. Huzarski | E. Pujade-Lauraine | S. Marschner | J. Ledermann | A. Savarese | M. O. Nicoletto | P. Combe | A. Amit | A. Allen | T. Enomoto | N. L. Milagro